TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$65 Million

X4 Pharmaceuticals, Inc.

Follow-on Offering

Lead Left Bookrunner, November 2019

X4 Pharmaceuticals, Inc.
X4 is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s pipeline is comprised of potentially first-in-class, oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (“PIs”) and certain types of cancer. X4’s lead product candidate, mavorixafor (X4P-001), is a potentially first-in-class, oral, allosteric antagonist of the CXCR4 receptor designed to correct the abnormal signaling caused by the receptor/ligand interaction and enable mobilization and trafficking of immune cells.